Consort Medical
VC Fund
Hemel Hempstead, United Kingdom
Consort Medical is a leading global contract development and manufacturing organisation (CDMO), providing advanced delivery technologies, formulation and manufacturing solutions for drugs.Their customers include some of the world’s largest pharmaceutical companies. Optimising world-class drug delivery device development and manufacture, togetherwith drug Active Pharmaceutical Ingredient (API) and finished dose formulation and manufacture, within the same Group streamlines and accelerates their pharmaceutical customers’ drug route to market.The Group is at the leading edge of innovation and is committed to investing in patient and customer driven innovation, with the potential to create new treatments, new markets and new opportunities.They also continue to diversify into adjacent complementary markets and technologies which leverage their core competencies in drug formulation, manufacturing and delivery.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Consort Medical invests in
Stages Consort Medical invests in
Countries Consort Medical invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Paul Hayes
|
|||
Peter Fellner
|
|||
Investment Focus
Industry
- Health Care 2 (67%)
- Mobile 1 (33%)
- Medical 1 (33%)
- Therapeutics 1 (33%)
- Biotechnology 1 (33%)
Stage
- Series A 1 (33%)
- Series C 1 (33%)
- Series D 1 (33%)
Country
- United States 1 (33%)
- United Kingdom 1 (33%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Paul Hayes
Chief Financial Officer
|
Chief Financial Officer | Total investments: 0 | Find email | |
|
Peter Fellner
Chairman
|
Chairman | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Binx Health is creating new categories of healthcare solutions that deliver on-demand testing to people where they need it most. With its proprietary, desktop, PCR-based point-of-care testing platforms and consumer mobile offerings, the company is redefining “convenient care” for the modern consumer | $35M / Series D / Jan 23, 2017 | ||
| Oxular is a clinical-stage retinal therapeutics company that is developing technology to transform the treatment of retinal disease, offering patients life-changing solutions to their unmet needs. | $20.6M / Series A / Jul 19, 2016 | ||
| Binx Health is creating new categories of healthcare solutions that deliver on-demand testing to people where they need it most. With its proprietary, desktop, PCR-based point-of-care testing platforms and consumer mobile offerings, the company is redefining “convenient care” for the modern consumer | $20M / Series C / Jan 29, 2015 |
Co-Investors
BB Biotech Ventures
2 deals together
Global Life Science Ventures
2 deals together
Johnson & Johnson Robotics and Digital Solutions
2 deals together
Novartis Venture Fund
2 deals together
RMI Partners
2 deals together
Technology Venture Partners
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Consort Medical invest in?
Consort Medical invests primarily in Health Care, Mobile and Medical startups, most often at Series A and Series C stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Consort Medical?
Public channels for Consort Medical include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Consort Medical?
The team at Consort Medical includes Paul Hayes (Chief Financial Officer) and Peter Fellner (Chairman). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
